查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2048431

癌症精準醫療市場－全球產業規模、佔有率、趨勢、機會、預測：生態系統、應用、區域及競爭格局（2021-2031）

Oncology Precision Medicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Ecosystem, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球腫瘤精準醫療市場預計將從 2025 年的 1,801.2 億美元成長到 2031 年的 3,238.2 億美元，複合年成長率為 10.27%。

這個領域的核心在於根據癌症患者特定的基因和分子特徵進行治療性介入化治療。市場成長的主要驅動力是全球惡性腫瘤發生率的上升和基因測序成本的下降，這促使人們需要更有效、更具針對性的治療策略。此外，巨量資料分析在臨床工作流程中的應用，有助於識別生物標記物，從而增加了對旨在最大限度減少藥物不良反應的個人化治療方法的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 1801.2億美元
市場規模：2031年 3238.2億美元
複合年成長率：2026-2031年 10.27%
成長最快的細分市場 詳細診斷
最大的市場 北美洲

然而，高昂的藥物研發成本和不一致的報銷政策給擴大市場准入帶來了巨大挑戰。再加上法規結構的複雜性，快速推廣這些先進治療方法就更加困難。儘管存在這些重大障礙，該領域仍保持著強大的韌性和創新能力。例如，美國藥品研究與製造商協會（PhRMA）的報告指出，到2024年，至少有15種新的癌症治療方法將獲得美國食品藥物管理局（FDA）的核准。這些數據凸顯了腫瘤學研究的持續發展勢頭，以及該行業致力於為患者提供精準治療方案的決心，即便麵臨經濟方面的挑戰。

市場促進因素

癌症發生率的不斷攀升，使得精準醫療成為改善病患預後的根本之選，其核心在於提供個人化治療。隨著癌症發生率的增加，醫療系統越來越依賴基因組分析來識別特定基因突變，推動了對標靶治療的需求，因為標靶治療的療效優於傳統化療。患者數量的激增，使得擴充性精準診斷技術成為應對複雜病例的迫切需求。美國癌症協會發布的《2024年癌症事實與數據》報告預測，美國每年新增癌症病例將首次超過200萬例。發病率的激增給臨床工作流程帶來了巨大壓力，也凸顯了向個人化醫療模式轉變的必要性。此外，世界衛生組織（WHO）下屬的國際癌症研究機構（IARC）在2024年預測，到2050年，全球癌症病例數可能超過3500萬例，這進一步強調了此類市場解決方案的長期需求。

同時，製藥公司和診斷公司之間的策略合作正透過整合資源開發下一代療法，加速市場擴張。這些合作在將科學發現快速轉化為臨床應用方面發揮關鍵作用，尤其是在抗體藥物複合體（ADC）和靶向放射性藥物領域。這一趨勢伴隨著大量的資本投資，旨在加強藥物研發管線並獲得整合新技術所需的專業知識。例如，2024年3月，強生公司宣布完成對Ambrx的收購，Ambrx是一家專注於新一代抗體偶聯物的臨床階段生物製藥公司，此次收購以約20億美元的以金額為準進行。此類大規模投資鞏固了精準腫瘤學的商業性可行性，並確保先進治療方法能夠持續引入醫療保健系統，同時有效克服研發成本的障礙。

市場挑戰

高昂的藥物研發成本和不一致的報銷政策是腫瘤精準醫療市場擴張的主要障礙。這些財務和管理方面的障礙使醫療服務提供者和藥物研發者對複雜治療方法的投資回報感到不確定性。由於支付方缺乏統一的基因組分析和標靶治療的保險覆蓋標準，患者獲得必要治療的機會受到限制。因此，醫療系統不願在沒有明確經濟補償的情況下採用昂貴的治療方案，從而延緩了精準醫療的普及，直接阻礙了市場收入成長。

這些經濟壓力正在影響市場規模，因為合格且能夠負擔得起這些治療的患者人數減少了。終端用戶面臨的經濟負擔是阻礙其更廣泛應用的一大限制。美國癌症協會癌症行動網路2024年的一項調查顯示，約48%的癌症倖存者和患者因支付治療費用而負債累累。這種「經濟負擔」迫使患者延後或放棄治療，導致全球精準腫瘤解決方案的整體普及率下降。

市場趨勢

將人工智慧 (AI) 應用於預測性基因組分析正在變革腫瘤學，加速標靶識別並最佳化臨床試驗。製藥公司正與科技公司合作，利用多模態真實世界數據加速開發精準的預測模型，進而降低藥物研發風險。這種方法採用深度學習演算法，比傳統方法更有效地對患者群體進行分層，以提高治療性介入的準確性。例如，2025 年 5 月，Tempus AI 宣布與勃林格殷格翰達成一項多年戰略合作，旨在透過在其整個腫瘤產品線中部署其人工智慧平台，加強數據驅動的治療研究。此類合作凸顯了產業向以人工智慧為中心的開發模式的轉變，這種模式能夠顯著縮短研發週期並提高臨床成功率。

同時，非侵入性液態生物檢體在分子殘留病灶（MRD）監測中的應用日益廣泛，正在為治療後後續觀察建立新的標準。這項技術能夠比基於影像學的複發檢測更早地識別循環腫瘤DNA（ctDNA），從而無需進行侵入性組織取樣即可實現快速干涉。隨著醫療機構將這些診斷方法整合到常規工作流程中，以主動管理復發風險，檢測數量正在迅速成長。 Natera公司在2025年8月發布的2025年第二季財報中宣布，該季度共進行了約188,800例腫瘤檢測，較去年同期成長50.6%。檢測數量的顯著成長表明，臨床上越來越依賴液態生物檢體解決方案，這些方案能夠為複雜癌症的治療提供即時、可操作的資訊。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：癌症精準醫療的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 基於生態系統的方法（精準診斷、精準治療、應用科學、數位健康、資訊科技）
    • 依應用領域（固體癌與骨髓惡性腫瘤）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美癌症精準醫療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲癌症精準醫療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區癌症精準醫療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲癌症精準醫療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲癌症精準醫療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球癌症精準醫療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • AstraZeneca
  • Genentech
  • Jiangsu Hengrui Pharmaceuticals
  • Johnson & Johnson Innovative Medicine
  • Novartis
  • Pfizer
  • SpringWorks Therapeutics
  • Bristol-Myers Squibb
  • Merck & Co., Inc.
  • Amgen Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 10709

The Global Oncology Precision Medicine Market is projected to expand from USD 180.12 Billion in 2025 to USD 323.82 Billion by 2031, reflecting a CAGR of 10.27%. This field centers on therapeutic interventions that customize medical treatment according to the specific genetic and molecular profiles of cancer patients. Market growth is primarily propelled by the rising global incidence of malignancies and declining genomic sequencing costs, which create a need for more effective and targeted therapeutic strategies. Additionally, the incorporation of big data analytics into clinical workflows facilitates biomarker identification, fueling the demand for personalized regimens designed to minimize adverse drug reactions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 180.12 Billion
Market Size 2031USD 323.82 Billion
CAGR 2026-203110.27%
Fastest Growing SegmentPrecision Diagnostics
Largest MarketNorth America

However, high drug development costs and inconsistent reimbursement policies pose significant challenges that could hinder broader market accessibility. The complexity of regulatory frameworks further adds to the difficulty of rapidly deploying these advanced therapies. Despite these substantial hurdles, the sector maintains strong resilience and innovation. For instance, PhRMA reported that at least 15 new cancer treatments received FDA approval in 2024. This data underscores the enduring momentum in oncology research and the industry's dedication to providing precision solutions to patients, even amidst economic barriers.

Market Driver

The increasing prevalence of oncological disorders creates a fundamental need for precision medicine to enhance patient outcomes through tailored therapies. As cancer rates rise, healthcare systems depend more heavily on genomic profiling to identify specific mutations, fueling the demand for targeted interventions that provide higher efficacy than traditional chemotherapy. This growth in patient volume generates an urgent requirement for scalable precision diagnostics to handle complex cases effectively. In its 'Cancer Facts & Figures 2024' report, the American Cancer Society projected that new U.S. cancer cases would exceed 2 million for the first time in a single year. This rising incidence places significant pressure on clinical workflows, validating the transition toward personalized care models. Furthermore, the World Health Organization's International Agency for Research on Cancer estimated in 2024 that the global cancer burden could surpass 35 million new cases by 2050, reinforcing the long-term necessity of these market solutions.

Concurrently, strategic partnerships between pharmaceutical companies and diagnostic firms are accelerating market expansion by pooling resources to develop next-generation therapeutics. These collaborations speed up the translation of scientific discoveries into clinical applications, especially regarding antibody-drug conjugates and targeted radiopharmaceuticals. This trend involves substantial capital investment to acquire specialized capabilities that strengthen drug pipelines and incorporate new technologies. For example, Johnson & Johnson announced in March 2024 that it completed the acquisition of Ambrx, a clinical-stage biopharmaceutical company focused on next-generation antibody-drug conjugates, for an equity value of roughly $2.0 billion. Such major financial commitments confirm the commercial viability of precision oncology and ensure the continuous introduction of advanced treatments into the healthcare system, effectively addressing development cost barriers.

Market Challenge

High drug development costs and inconsistent reimbursement policies serve as major barriers to the expansion of the oncology precision medicine market. These financial and administrative obstacles create uncertainty for healthcare providers and pharmaceutical developers regarding the return on investment for complex therapies. The lack of uniform coverage standards from payers for genomic profiling and targeted agents limits patient access to essential treatments. Consequently, the adoption of precision medicine is delayed because healthcare systems are reluctant to implement expensive protocols without assured financial coverage, which directly impedes market revenue growth.

This economic pressure impacts market volume by reducing the number of eligible patients able to afford these interventions. The financial burden placed on end-users acts as a critical constraint preventing broader adoption. A 2024 survey by the American Cancer Society Cancer Action Network revealed that approximately 48 percent of cancer survivors and patients went into debt to pay for their care. This financial toxicity compels patients to postpone or skip treatment, thereby lowering the overall penetration rate of precision oncology solutions within the global sector.

Market Trends

The integration of Artificial Intelligence (AI) into predictive genomic profiling is transforming oncology by speeding up target identification and optimizing clinical trials. Pharmaceutical companies are partnering with technology firms to utilize multimodal real-world data, facilitating the creation of precise predictive models that reduce risks in drug discovery. This approach employs deep learning algorithms to stratify patient populations more effectively than traditional methods, thereby improving the accuracy of therapeutic interventions. For instance, in May 2025, Tempus AI announced a multi-year strategic collaboration with Boehringer Ingelheim to implement its AI-enabled platform across the pharmaceutical company's oncology pipeline, aiming to bolster data-driven therapeutic research. These collaborations confirm the industry's shift toward AI-centric development models, which notably shorten timelines and boost clinical success rates.

Simultaneously, the widespread adoption of non-invasive liquid biopsy for Molecular Residual Disease (MRD) monitoring is setting a new benchmark for post-treatment surveillance. This technology identifies circulating tumor DNA (ctDNA) significantly earlier than radiological relapse, allowing for prompt interventions without invasive tissue sampling. The market is experiencing a rapid increase in test volumes as providers incorporate these diagnostics into routine workflows to proactively manage recurrence risks. In its 'Second Quarter 2025 Financial Results' report from August 2025, Natera stated it performed approximately 188,800 oncology tests during the quarter, representing a 50.6% increase year-over-year. This significant growth in volume underscores the increasing clinical dependence on liquid biopsy solutions for providing real-time, actionable insights in complex cancer management.

Key Market Players

  • AstraZeneca
  • Genentech
  • Jiangsu Hengrui Pharmaceuticals
  • Johnson & Johnson Innovative Medicine
  • Novartis
  • Pfizer
  • SpringWorks Therapeutics
  • Bristol-Myers Squibb
  • Merck & Co., Inc.
  • Amgen Inc.

Report Scope

In this report, the Global Oncology Precision Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oncology Precision Medicine Market, By Ecosystem

  • Precision Diagnostics
  • Precision Therapeutics
  • Applied Sciences
  • Digital Health
  • Information Technology

Oncology Precision Medicine Market, By Application

  • Solid Tumor
  • Hematological Malignancies

Oncology Precision Medicine Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Oncology Precision Medicine Market.

Available Customizations:

Global Oncology Precision Medicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oncology Precision Medicine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Ecosystem (Precision Diagnostics, Precision Therapeutics, Applied Sciences, Digital Health, Information Technology)
    • 5.2.2. By Application (Solid Tumor v/s Hematological Malignancies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Oncology Precision Medicine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Ecosystem
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Oncology Precision Medicine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Ecosystem
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Oncology Precision Medicine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Ecosystem
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Oncology Precision Medicine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Ecosystem
        • 6.3.3.2.2. By Application

7. Europe Oncology Precision Medicine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Ecosystem
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Oncology Precision Medicine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Ecosystem
        • 7.3.1.2.2. By Application
    • 7.3.2. France Oncology Precision Medicine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Ecosystem
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Oncology Precision Medicine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Ecosystem
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Oncology Precision Medicine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Ecosystem
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Oncology Precision Medicine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Ecosystem
        • 7.3.5.2.2. By Application

8. Asia Pacific Oncology Precision Medicine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Ecosystem
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Oncology Precision Medicine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Ecosystem
        • 8.3.1.2.2. By Application
    • 8.3.2. India Oncology Precision Medicine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Ecosystem
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Oncology Precision Medicine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Ecosystem
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Oncology Precision Medicine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Ecosystem
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Oncology Precision Medicine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Ecosystem
        • 8.3.5.2.2. By Application

9. Middle East & Africa Oncology Precision Medicine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Ecosystem
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Oncology Precision Medicine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Ecosystem
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Oncology Precision Medicine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Ecosystem
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Oncology Precision Medicine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Ecosystem
        • 9.3.3.2.2. By Application

10. South America Oncology Precision Medicine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Ecosystem
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Oncology Precision Medicine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Ecosystem
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Oncology Precision Medicine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Ecosystem
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Oncology Precision Medicine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Ecosystem
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Oncology Precision Medicine Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AstraZeneca
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Genentech
  • 15.3. Jiangsu Hengrui Pharmaceuticals
  • 15.4. Johnson & Johnson Innovative Medicine
  • 15.5. Novartis
  • 15.6. Pfizer
  • 15.7. SpringWorks Therapeutics
  • 15.8. Bristol-Myers Squibb
  • 15.9. Merck & Co., Inc.
  • 15.10. Amgen Inc.

16. Strategic Recommendations

17. About Us & Disclaimer